Direct Xa inhibitors in acute coronary syndrome.
نویسندگان
چکیده
cute coronary syndrome (ACS) is the major cause of morbidity and mortality in the world. Recent developments in ACS treatment have significantly improved the prognosis of ACS patients, but the risk of recurrent ischemic events remains still high.1 Even with dual antiplatelet therapy (DAPT), death, myocardial infarction (MI), or stroke occurs in 9–11% at 1 year after the ACS event.2 One potential strategy is the addition of anticoagulant after initial hospitalbased management.
منابع مشابه
A new paradigm shift in antithrombotic therapy
Decades after the introduction of oral anti-coagulants namely the vitamin K antagonist (VKA) Warfarin and antiplatelet agents such as Aspirin and Plavix, new classes of direct, small molecule, novel oral anti-coagulant medications and antiplatelet P2Y12 receptor inhibitors have recently become available. For the novel oral anticoagulants (NOAC), these agents can be separated by direct thrombin ...
متن کاملClinical utility of rivaroxaban in stroke prevention associated with nonvalvular atrial fibrillation – patient considerations
The direct factor Xa inhibitor rivaroxaban was the first within the group of orally available direct factor Xa inhibitors to gain clinical approval for oral anticoagulation in patients with nonvalvular atrial fibrillation in 2011. The -xabans, as drugs from the group of oral direct factor Xa inhibitors are often referred to, comprise currently three drugs (apixaban, edoxaban, and rivaroxaban) w...
متن کاملRole of oral factor Xa inhibitors after acute coronary syndrome.
Despite an early invasive strategy and the use of dual antiplatelet therapy, patients with acute coronary syndrome (ACS) continue to be at substantial risk for recurrent ischemic events. It is believed that this risk is, at least in part, due to an intrinsic coagulation pathway that remains activated for a prolonged period after ACS. Earlier studies using warfarin showed a reduction in ischemic...
متن کاملBleeding Disorders Surgery at High Risk of Bleeding
(VTE) and in some countries for the treatment of acute coronary syndromes. Idraparinux, a subcutaneous, longacting, indirect Factor Xa inhibitor, is in development. Direct inhibition of thrombin or Factor Xa with synthetic, small molecules is an attractive strategy for the development of novel anticoagulants. After the withdrawal of ximelagatran, dabigatran is now the furthest advanced oral, di...
متن کاملUse of new-generation oral anticoagulant agents in patients receiving antiplatelet therapy after an acute coronary syndrome: systematic review and meta-analysis of randomized controlled trials.
BACKGROUND Despite receipt of dual antiplatelet therapy, patients after an acute coronary syndrome (ACS) remain at significant risk for thrombotic events. The role of orally activated Xa antagonist (anti-Xa) and direct thrombin inhibitors is debated in this setting. Our study objective was to evaluate the efficacy and safety of new-generation oral anticoagulant agents compared with placebo in p...
متن کاملAnticoagulants in heart disease: current status and perspectives.
List of abbreviations . . . . . . . . . . . . . . . . . . 2 Preamble: purposes and scope of the task force . . 2 Blood coagulation . . . . . . . . . . . . . . . . . . . . 3 Haemostasis . . . . . . . . . . . . . . . . . . . . . 3 Arterial thrombosis . . . . . . . . . . . . . . . . . 3 Tissue factor . . . . . . . . . . . . . . . . . . . . . 3 Tissue factor pathway inhibitor . . . . . . . . . . 3 ...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- Circulation journal : official journal of the Japanese Circulation Society
دوره 77 9 شماره
صفحات -
تاریخ انتشار 2013